Annual report pursuant to Section 13 and 15(d)

SEGMENT REPORTING (Tables)

v3.21.1
SEGMENT REPORTING (Tables)
12 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table is a comparative summary of the Company’s net sales and segment profit for by reportable segment for the periods presented:
Year ended
  December 31,
2020
December 31,
2019
Segment Net Sales:
Cannabinoid $ 2,511  $ 133 
Non-Cannabinoid 9,606  7,701 
Total Net Sales 12,117  7,834 
 
Segment Profit (Loss):
Cannabinoid (18,798) (25,250)
Non-Cannabinoid 1,863  614 
Total Loss $ (16,935) $ (24,636)
 
Reconciliation:
Total Segment Loss (16,935) (24,636)
Unallocated corporate expenses (6,405) (5,887)
Non-cash share based compensation (1,652) (1,522)
Depreciation and amortization (1,854) (1,480)
Herbal Brands acquisition related charges   (3,015)
Goodwill impairment (1,682) — 
Loss from operations $ (28,528) $ (36,540)
 
Loss on debt extinguishment 2,360  3,374 
Loss on fair value of derivative instrument 657  421 
Loss on investments 464  756 
Foreign exchange loss 491  1,575 
Interest expense 4,455  2,684 
Miscellaneous, net (284) 534 
Loss from operations before income taxes $ (36,671) $ (45,884)
December 31,
2020
December 31,
2019
Long-lived assets
   
Cannabinoid $ 25,485  $ 24,209 
Non-Cannabinoid
176  207 
Other(a)
19  16 
  $ 25,680  $ 24,432 
____________
(a)“Other” includes long-lived assets primarily in the Company’s corporate offices.
Disaggregation of Revenue by Channel
The following table disaggregates the Company’s revenues by channel for the for the periods presented:
  Year ended
  December 31,
2020
December 31,
2019
Mass retail $ 6,879  $ 3,318 
Specialty, health and other retail 689  1,235 
Distributors 4,036  2,397 
E-commerce 513  885 
$ 12,117  $ 7,834